Tag Archives: driver mutation
Dr. Greg Riely (Pt 2): Should local ablation therapy in oligometastatic or oligoprogressing cancer be incorporated into routine practice?
Dr. Greg Riely (Pt 1): Current Practice & Challenges in Execution of Genomic Testing in Lung Cancer Treatment
Dr. Charu Aggarwal (Part 1): Growing Momentum for Plasma-Based NGS Testing in Advanced NSCLC
Small Trial Shows Big Risks of Giving First Line Pembrolizumab to EGFR Mutation-Positive Patients, Even with High Tumor PD-L1 Expression (BMIC-042)
Dr. Jack West summarizes a small trial from UCLA that tests the utility of giving first line immunotherapy to EGFR mutation-positive patients with high tumor PD-L1 expression, which led to poor outcomes that should cast a long shadow on this approach. (7:11)
Is immunotherapy ineffective in patients with driver mutation-positive advanced NSCLC? Time to walk that back. (BMIC-027)
Dr. Jack West summarizes the evolving data shaping our understanding of the role of immune checkpoint inhibitors for patients with EGFR- or ALK-positive advanced NSCLC, including more recent data that should change our perspective. (10:25)
Genomic Sequencing for All Solid Tumors: Where Will This Lead Us? (BMIC-019)
Dr. Jack West reviews the implications, both encouraging and potentially detrimental, of a recent FDA approval for broad genomic (NGS) testing of all solid tumors, ushering in a new era of growing precision medicine and molecular oncology. (8:55)
New Target & Treatment in Advanced NSCLC: Dabrafenib/Trametinib for BRAF V600E Mutation-Positive NSCLC (BMIC-018)
Dr. Jack West reviews data on the FDA-approved combination of dabrafenib/trametinib for patients with BRAF V600E mutation-positive advanced NSCLC, as published by Planchard & colleagues in Lancet Oncology. (6:24)